These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30309223)

  • 1. Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology.
    Ha H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Res Treat; 2019 Apr; 51(2):832-840. PubMed ID: 30309223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients.
    Park W; Bang JH; Nam AR; Jin MH; Seo H; Kim JM; Oh KS; Kim TY; Oh DY
    Cancer Res Treat; 2021 Jan; 53(1):199-206. PubMed ID: 33070562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Jin MH; Oh KS; Kim JM; Kim TY; Oh DY
    Liver Int; 2021 Feb; 41(2):388-395. PubMed ID: 32780918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
    Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
    Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
    Park H; Bang JH; Nam AR; Park JE; Jin MH; Bang YJ; Oh DY
    Cancer Med; 2020 Jan; 9(1):43-51. PubMed ID: 31701645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
    Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
    Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
    Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
    Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
    ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.